Recent Company News

• 04:59 AM ET Aug 28, 2026
  

  CSPC Pharmaceutical Group initiates phase II clinical trial of SYH2069 injection for weight management in China (HK$9.53, 0.00)

• 05:17 AM ET Aug 27, 2026
  

  NMPA approves trial of CSPC Innovation Pharmaceutical unit's SYH2092 (CNY 46.95, 0.00)

• 06:05 AM ET Aug 26, 2026
  

  CSPC Pharma's SYS6010 has met primary endpoint of PFS in its phase III trial for treatment of NSCLC (HK$9.53, 0.00)

• 04:21 AM ET Aug 26, 2026
  

  CSPC Innovation Pharmaceutical unit's phase III trial of SYS6010 for EGRF-mutant NSCLC meets PFS primary endpoint (CNY 45.50, 0.00)

• 04:10 AM ET Aug 26, 2026
  

  FDA grants fast track designation for CSPC Innovation Pharmaceutical unit's SYS6090 for MSS or pMMR mCRC (CNY 45.50, 0.00)

• 09:23 AM ET Aug 25, 2026
  

  CSPC Pharmaceutical Group's SYS6010 to be granted breakthrough therapy designation by China's NMPA in head and neck squamous cell carcinoma (HK$9.41, 0.00)

• 07:19 AM ET Aug 25, 2026
  

  CSPC Pharmaceutical Group obtains US FDA clinical trial approval for RSV vaccine SYS6057 (HK$9.41, 0.00)

• 09:43 PM ET Aug 21, 2026
  

  CSPC Pharmaceutical Group upgraded to buy at UOB Kay Hian Securities (HK$9.19, 0.00)

• 06:02 AM ET Aug 21, 2026
  

  Street Takeaways - CSPC Pharmaceutical Group H1 earnings (HK$9.19, 0.00)

• 12:46 AM ET Aug 20, 2026
  

  StreetAccount Metrics Recap - CSPC Pharmaceutical Group H1 Earnings (HK$9.86, +1.17)